Genmab (GMAB)

Genmab and BioNTech Expand Global Strategic Collaboration to Develop and Commercialize Novel Immunotherapy Candidates

Keros Therapeutics Inc (KROS)

(10% Negative) Keros Therapeutics, Inc. (KROS) Announces Delay in trials Trials for KER-050 Due to Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment